BiohavenBHVN
Neurology26 cited findings · profile updated 2026-08-26
14.38 USDnot live — refreshed daily
About Biohaven
Biohaven (BHVN) focuses on neurology. The company is developing Opakalim, which demonstrated a median time to second generalized tonic-clonic seizure of 141 days, compared to 47 days for placebo. In studies, 54% of subjects achieved a ≥50% reduction in seizure frequency with Opakalim. Additionally, 20% of Opakalim-treated subjects completed a 24-week double-blind phase seizure-free, while 0% of placebo subjects achieved this.
Another licensed product, BHV-7000, is being studied for Refractory Focal Onset Epilepsy in clinical studies RISE 2 (NCT06132893) and RISE 3 (NCT06309966). Opakalim also showed a 50% reduction in seizure counts in a KCNQ2-DEE patient. Top-line results for pivotal Phase 2/3 studies for Opakalim are expected in 2H 2026. Rates of CNS AEs (somnolence, dizziness, fatigue, memory impairment) for Opakalim were ≤5%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Median time to second generalized tonic-clonic seizure | 141 days (Opakalim) vs 47 days (placebo) | Biohaven Ltd. — SEC 8-K (2026-05-27), p.1 |
| Subjects achieving ≥50% reduction in seizure frequency | 54% (Opakalim) | Biohaven Ltd. — SEC 8-K (2026-05-27), p.3 |
| Opakalim-treated subjects completing 24-week double-blind phase seizure-free | 20% | Biohaven Ltd. — SEC 8-K (2026-05-27), p.3 |
| Placebo subjects completing 24-week double-blind phase seizure-free | 0% | Biohaven Ltd. — SEC 8-K (2026-05-27), p.3 |
| Reduction in seizure counts (KCNQ2-DEE patient) | 50% (Opakalim) | Biohaven Ltd. — SEC 8-K (2026-05-27), p.4 |
| Rates of CNS AEs (somnolence, dizziness, fatigue, memory impairment) | ≤5% (Opakalim) | Biohaven Ltd. — SEC 8-K (2026-05-27), p.1 |
Key projects
- Opakalim (generalized tonic-clonic seizures)
The median time to second generalized tonic-clonic seizure was 141 days with Opakalim, compared to 47 days for placebo.
- Opakalim (seizure frequency reduction)
54% of subjects achieved a ≥50% reduction in seizure frequency with Opakalim.
- Opakalim (KCNQ2-DEE patient)
Opakalim demonstrated a 50% reduction in seizure counts in a KCNQ2-DEE patient.
- BHV-7000 Licensed Product (Refractory Focal Onset Epilepsy)
BHV-7000 Licensed Product is being studied for Refractory Focal Onset Epilepsy in clinical studies RISE 2 and RISE 3.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Neurology research library →